다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Laboratory animal research, v.36, 2020년, pp.26 -
Kim, Dae-geon (Department of Veterinary Physiology, College of Veterinary Medicine, Gyeongsang National University, Jinju, 52828 Republic of Korea) , Kwon, Hyo-Jeong (Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam National University, Daejeon, 34134 Republic of Korea) , Lim, Jong-Hwan (Huons Research Center, Ansan, Gyeonggi-do 15588 Republic of Korea) , Kim, Joo-heon (Department of Veterinary Physiology, College of Veterinary Medicine, Gyeongsang National University, Jinju, 52828 Republic of Korea) , Lee, Kyu Pil (Department of Veterinary Physiology, College of Veterinary Medicine, Chungnam National University, Daejeon, 34134 Republic of Korea)
AI-Helper
Benign prostate hyperplasia (BPH) is a common disease in old-age males, accounting for approximately 77% of morbidity within the age range of 40 to 70 years. It has been shown that morbidity increases with social graying. Quisqualis indica linn (QI) has been used to treat inflammation, stomach pain,...
1. Barkin J Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management Can J Urol 2011 18 1 14 21501546
2. Carruthers SG Adverse effects of α 1-adrenergic blocking drugs Drug Saf 1994 11 1 12 20 10.2165/00002018-199411010-00003 7917078
3. Choi BR Soni KK Zhang LT Lee SW So I Kim HK Park JK Effect of 4-chloro-7-trifluoromethyl-10H-benzo [4,5] furo [3,2-b]indole-1-carboxylic acid on the intraurethral pressure in a rat model of benign prostatic hyperplasia Int J Urol 2016 23 3 259 265 10.1111/iju.13018 26646436
4. Desgrandchamps F Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS Curr Opin Urol 2004 14 1 17 20 10.1097/00042307-200401000-00004 15091044
5. Fwu C-W Eggers PW Kirkali Z McVary KT Burrows PK Kusek JW Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy J Urol 2014 191 6 1828 1834 10.1016/j.juro.2013.12.014 24342143
6. Girman C Population-based studies of the epidemiology of benign prostatic hyperplasia Br J Urol 1998 82 34 10.1046/j.1464-410X.1998.0820s1034.x 9883260
7. Kambar Y Asha M Chaithra M Kekuda PT Antibacterial activity of leaf and flower extract of Quisqualis indica Linn. against clinical isolates of Staphylococcus aureus Res J Sci Technol 2014 6 1 23
8. Kang KK Kim JM Yu JY Ahn BO Yoo M Kim YC Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia Int J Urol 2007 14 10 946 951 10.1111/j.1442-2042.2007.01874.x 17880297
9. Kontani H Shiraoya C Method for simultaneous recording of the prostatic contractile and urethral pressure responses in anesthetized rats and the effects of tamsulosin Jpn J Pharmacol 2002 90 3 281 290 10.1254/jjp.90.281 12499584
10. McVary KT Erectile dysfunction and lower urinary tract symptoms secondary to BPH Eur Urol 2005 47 6 838 845 10.1016/j.eururo.2005.02.001 15925081
11. McVary KT Roehrborn CG Avins AL Barry MJ Bruskewitz RC Donnell RF Foster HE Gonzalez CM Kaplan SA Penson DF Update on AUA guideline on the management of benign prostatic hyperplasia J Urol 2011 185 5 1793 1803 10.1016/j.juro.2011.01.074 21420124
12. Mebust W Holtgrewe H Cockett A Peters P Transurethral prostatectomy: immediate and postoperative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients J Urol 2002 167 1 5 9 10.1016/S0022-5347(05)65370-0 11743263
13. Mondaini N Gontero P Giubilei G Lombardi G Cai T Gavazzi A Bartoletti R Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007 4 6 1708 1712 10.1111/j.1743-6109.2007.00563.x 17655657
14. Nascimento-Viana JB Carvalho AR Nasciutti LE Alcantara-Hernandez R Chagas-Silva F Souza PA Romeiro LA Garcia-Sainz JA Noel F Silva CL New multi-target antagonists of alpha1A-, alpha1D-adrenoceptors and 5-HT1A receptors reduce human hyperplastic prostate cell growth and the increase of intraurethral pressure J Pharmacol Exp Ther 2016 356 1 212 222 10.1124/jpet.115.227066 26493747
15. Oh SH Oh BR Ryu SB Effect of finasteride on sexual function in patients with benign prostatic hyperplasia Korean J Urol 2002 43 7 611 618
16. Patel ND Parsons JK Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction Indian J Urol 2014 30 2 170 10.4103/0970-1591.126900 24744516
17. Roehrborn C Pathology of benign prostatic hyperplasia Int J Impot Res 2008 20 S3 S11 10.1038/ijir.2008.55
18. Roehrborn CG Casabe A Glina S Sorsaburu S Henneges C Viktrup L Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo Int J Urol 2015 22 6 582 587 10.1111/iju.12741 25827166
19. Rosen R Altwein J Boyle P Kirby RS Lukacs B Meuleman E O’Leary MP Puppo P Robertson C Giuliano F Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 2003 44 6 637 649 10.1016/j.eururo.2003.08.015 14644114
20. Ub Wijerathne C Park H-S Jeong H-Y Song J-W Moon O-S Seo Y-W Won Y-S Son H-Y Lim J-H Yeon S-H Kwun H-J Quisqualis indica improves benign prostatic hyperplasia by regulating prostate cell proliferation and apoptosis Biol Pharm Bull 2017 40 12 2125 2133 10.1248/bpb.b17-00468 28943529
21. Walsh P Hutchins G Ewing L Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal J Clin Invest 1983 72 5 1772 1777 10.1172/JCI111137 6195192
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.